Prognostic Marker for Endometrial Carcinoma

A method for evaluating the probability of survival for an individual suffering from endometrial carcinoma or the clinical outcome comprising the step of determining alterations, in particular, amplifications and deletions, of chromosomal regions 3q26.32 and 12p12.1, alterations of the gene expression profile of the genes (gene signature):

• upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes:
• NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein.

A method for diagnosing or identifying endometrial carcinoma with high grade aggressive phenotype in a subject comprising

• a) determining the level or amount of STMN1 in a sample of said subject;
• and
• b) comparing the level or amount determined in step a) to a reference value, wherein an increase in the level or amount relative to the reference value is indicative for endometrial carcinoma with high grade aggressive phenotype.

A method for the stratification of the therapy of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer in an individual or monitoring therapeutic efficacy of said diseases in an individual comprising the step of determining the expression status of the STMN1 gene or protein and stratifying the therapy or monitoring the efficacy of therapy of the endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer in said individual.

A kit for use in providing a diagnosis or differentiation of endometrial carcinoma in an individual, for the stratification of endometrial tumor therapy in an individual, monitoring therapeutic efficacy in an individual, or for evaluating the probability of survival for an individual suffering from endometrial carcinoma comprising means for determining alterations, in particular, amplifications and deletions, of chromosomal regions 3q26.32 and 12p12.1, alterations of the gene expression profile of the genes (gene signature):

• upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes:
• NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein.